Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Kindred Biosciences (KIN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 490,945
  • Shares Outstanding, K 33,800
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,880 K
  • 36-Month Beta 0.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.40
  • Number of Estimates 2
  • High Estimate -0.38
  • Low Estimate -0.42
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -37.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.35 +16.60%
on 07/18/18
15.75 -8.57%
on 08/13/18
+1.85 (+14.74%)
since 07/17/18
3-Month
9.35 +54.01%
on 05/21/18
15.75 -8.57%
on 08/13/18
+4.45 (+44.72%)
since 05/17/18
52-Week
6.55 +119.85%
on 08/18/17
15.75 -8.57%
on 08/13/18
+7.65 (+113.33%)
since 08/17/17

Most Recent Stories

More News
Kindred Biosciences Announces Second Quarter 2018 Financial Results

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June...

KIN : 14.40 (-0.86%)
Kindred Biosciences to Announce Second Quarter 2018 Financial Results

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its second quarter 2018 financial...

KIN : 14.40 (-0.86%)
Kindred Biosciences Announces Commercial Availability of Mirataz® (mirtazapine transdermal ointment) to Veterinarians in the United States

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that Mirataz® (mirtazapine transdermal ointment)...

KIN : 14.40 (-0.86%)
Kindred Biosciences Announces Exercise of Option to Purchase Additional Shares and Closing of Public Offering of Common Stock

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, announced the underwriters have exercised in full their option to...

KIN : 14.40 (-0.86%)
Kindred Biosciences Announces the Termination of Its At-The-Market Equity Offering Program

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the termination of its "at-the-market" equity offering...

KIN : 14.40 (-0.86%)
Kindred Biosciences Announces Pricing of Public Offering

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of an underwritten public offering of...

KIN : 14.40 (-0.86%)
Kindred Biosciences Announces Proposed Public Offering of Common Stock

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced a proposed public offering of its common stock....

KIN : 14.40 (-0.86%)
KindredBio Announces Positive Results from Pilot Effectiveness Study of KIND-014 for the Treatment of Gastric Ulcers in Horses

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from its pilot field effectiveness...

KIN : 14.40 (-0.86%)
Kindred Biosciences to Present at Jefferies 2018 Global Healthcare Conference and 8th Annual LD Micro Invitational Conference

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the 8th Annual LD Micro Invitational Conference...

KIN : 14.40 (-0.86%)
Kindred Biosciences to Present at Stifel 2018 Dental & Veterinary Conference

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Stifel 2018 Dental & Veterinary Conference on...

KIN : 14.40 (-0.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade KIN with:

Business Summary

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have...

See More

Key Turning Points

2nd Resistance Point 14.80
1st Resistance Point 14.60
Last Price 14.40
1st Support Level 14.25
2nd Support Level 14.10

See More

52-Week High 15.75
Last Price 14.40
Fibonacci 61.8% 12.24
Fibonacci 50% 11.15
Fibonacci 38.2% 10.06
52-Week Low 6.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar